Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022年7月8日 - 9:00PM
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or
“Viridian”), a biotechnology company advancing new treatments for
patients suffering from serious diseases but underserved by current
therapies, today announced that a majority of the independent
directors serving on the Compensation Committee of the Company’s
Board of Directors approved the grant of stock options to an
employee to purchase 14,000 shares of the Company’s common stock
(the “Inducement Grant”) on July 1, 2022 (the “Grant Date”). The
Inducement Grant has been granted outside of the Company’s Amended
and Restated 2016 Equity Incentive Plan (the “Plan”) but remains
subject to the terms and conditions of such Plan. The Inducement
Grant was granted as an inducement material to this individual
entering into employment with Viridian in accordance with Nasdaq
Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is
equal to the closing price of Viridian’s common stock on the Grant
Date. The Inducement Grant will vest over a four-year period, with
25% of the shares vesting on the one-year anniversary of the
employee’s start date, and thereafter the remainder of the shares
vest in 36 equal monthly installments, subject to continued
employment through the applicable vesting dates.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). Viridian’s second product candidate, VRDN-002, is a
distinct anti-IGF-1R antibody that incorporates half-life extension
technology and is designed to support administration as a
convenient, low-volume, subcutaneous injection. TED is a
debilitating autoimmune disease that causes inflammation and
fibrosis within the orbit of the eye which can cause double vision,
pain, and potential blindness. Patients with severe disease often
require multiple remedial surgeries to the orbit, eye muscles and
eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media ContactJohn JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2024 まで 7 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 7 2023 まで 7 2024